Kuros Biosciences Ltd (CSBTF)
8.33
+0.36
(+4.58%)
USD |
OTCM |
Apr 17, 09:40
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 306.27M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 321.4% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.090 |
| Price to Book Value | 4.536 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 95.00% |
Profile
| Kuros Biosciences Ltd is a biotechnology company that focuses on the discovery, development and prospective commercialization of a new class of bio-pharmaceutical products for use in the treatment and prevention of chronic diseases. The company is also developing a family of bone healing products to address indications in trauma, and spine as well as sealants which provides reliable closure of tissue membranes to ensure functional integrity after surgery or trauma. The pipeline products of the company are Synthetic Orthobiologics, Fibrin Orthobiologics, and Sealants. The majority of the company's revenue comes from the United States. |
| URL | https://kurosbio.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Kuros Biosciences Ltd is a biotechnology company that focuses on the discovery, development and prospective commercialization of a new class of bio-pharmaceutical products for use in the treatment and prevention of chronic diseases. The company is also developing a family of bone healing products to address indications in trauma, and spine as well as sealants which provides reliable closure of tissue membranes to ensure functional integrity after surgery or trauma. The pipeline products of the company are Synthetic Orthobiologics, Fibrin Orthobiologics, and Sealants. The majority of the company's revenue comes from the United States. |
| URL | https://kurosbio.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |